Teva’s chief drug Austedo—approved in Huntington’s disease and tardive dyskinesia—grew sales 19% to $498 million for the ...

Teva Pharmaceuticals swung to a second-quarter profit though narrowed its full-year adjusted earnings guidance. The Israeli based pharmaceutical company posted a second-quarter profit of $282 million, ...

Teva Pharmaceutical Industries reported a better than expected increase in second-quarter profit on Wednesday, helped by a 26 ...

Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.

In recent health news, WuXi Apptec plans a $980 million share expansion, nursing strikes erupt in Nigeria, Teva ...

Reported EPS is $0.2429 EPS, expectations were $0.63. Operator: Hello, and welcome to the Teva Pharmaceutical Industries ...

B. Braun Medical, the third largest medical device maker in Orange County, is set to finish a $500 million modernization of ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

The majority of Teva's business lies in generic and off-patent branded drugs which faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...

On the same day last week that the Centers for Medicare and Medicaid Services rolled out plans to ease the flow of health ...

Eli Lilly’s Jaypirca (pirtobrutinib) has been shown to be superior to Johnson & Johnson (J&J) and AbbVie’s star Bruton's ...

The proposed duties—linked to India’s high tariffs, non-tariff barriers, and Russia ties—could disrupt key sectors like ...